

Proactive TDM Versus Standard Use of Biologics in Psoriasis

NCT06398106

Status	RECRUITING
Phase	Phase 4
Sponsor	University Hospital, Ghent
Enrollment	210 participants

Key Eligibility Criteria

Inclusion (4)

- Adults; aged 18 years or older
- Documented diagnosis of psoriasis (predominantly type vulgaris; based on clinical diagnosis) by an accredited dermatologist
- Patients must be currently treated with secukinumab, ixekizumab or guselkumab e 6 months according to the standard dosing scheme.
- The subject signs and dates a written informed consent form and any required privacy authorization prior to the initiation of any study procedures

Exclusion (5)

- Another indication than plaque psoriasis as the main indication for biologic use (e.g. receives biologic for rheumatoid arthritis as the main indication)
- Concomitant use of systemic immunosuppressants other than methotrexate or acitretin (e.g. prednisone, cyclosporine etc)
- Severe comorbidities with short life-expectancy (e.g. metastasized tumour) or uncontrolled PSA at inclusion/baseline
- Presumed inability to follow the study protocol
- Active pregnancy wish

Locations (15 total)

AZ Sint-Jan, Bruges, Belgium
CHU Saint-Pierre, Brussels, Belgium
UCL Saint-Luc, Brussels, Belgium
... and 12 more locations